Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040425 (tonsillitis)
 1,594 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

As a result of conducting experimental and clinical tests with the newly developed cephalosporin, cefoperazone (CPZ), the following conclusions were obtained: (1) When tested against 10 strains of Staphylococcus aureus and 16 strains of Staphylococcus epidermidis, the antibacterial activity of CPZ was found to be weaker than that of CEZ. Against 5 strains of A-beta-Streptococcus and 4 strains of Streptococcus pneumoniae, both CPZ and CEZ exhibited similar excellent antibacterial activity. CPZ was effective against 18 strains of Escherichia coli though its activity was influenced by the amount of inoculated bacteria present. Against 15 strains of Haemophilus influenzae and 10 strains of Haemophilus parahaemolyticus, CPZ was found to be more effective than CEZ though several high-resistant strains were noted. CPZ also showed more excellent antibacterial activity than CEZ against 4 strains of Haemophilus parainfluenzae, 5 strains of Klebsiella pneumoniae, 8 strains of Salmonella sp., 4 strains of Pseudomonas aeruginosa and 4 strains of Proteus sp. (2) The mean half-life in the blood following intravenous injections of 25 mg/kg and 10 mg/kg of CPZ to three children was 70 minutes. (3) One hour after intravenous injection of 25 mg/kg of CPZ to 3 cases of aseptic meningitis, drug concentration in the cerebrospinal fluid (CSF) was 1.20 mcg/ml, less than 0.39 mcg/ml and 1.55 mcg/ml. In one case, the CSF/serum ratio was 2.7%. (4) The average recovery rate in the urine of children who had received intravenous administrations of 25 mg/kg (3 children) and 10 mg/kg (1 child) was 17.8% between 0 and 6 hours. (5) Eighteen pediatric patients received CPZ in doses ranging from 48 to 170 mg/kg divided three-four times a day. They were RTI in 7, URI in 5, UTI in 5, SSSS in 1 and enteritis in 1 children. The clinical effectiveness of CPZ was judged to be remarkedly effective in 11 children, effective in 5 children and ineffective in 3 children, with an overall effective rate of 84.2%. One patient of tonsillitis combined sinusitis was considered 2 cases. The three cases in which the drug was found to e ineffective were 2 cases of pyothorax and 1 case of sinusitis. (6) Side effects were 1 case of eosinophilia, 2 cases of elevation of GOT and GPT, and 1 case of mild elevation of GOT. All were considered to be minor.
 ...
PMID:[Fundamental and clinical studies of cefoperazone in children (author's transl)]. 645 30

1. MIC of 6059-S against 92 strains of clinically isolated bacteria were measured. The compound was active against most of Gram-negative rods, but was not active against Staphylococcus aureus. 2. 20 mg/kg of 6059-S (newly synthesized oxacephem antibiotics) was administered to the pediatric patients and its blood concentration was measured by agar well method using E. coli 7437 as a test organism. 3. The mean blood concentrations were maximum at 15 minutes after intravenous one-bolus injection. Maximum levels were 94.5 mcg/ml in the patients of below 5 years old and 98.7 mcg/ml above 6 years old. Their half-life of the blood levels were 95.4 and 110.6 minutes respectively. 4. The mean blood concentrations were highest at the end of the infusion in the cases of 60 minutes drip injection. Maximum levels were 85.0 mcg/ml in the patients of below 5 years old and 64.8 mcg/ml above 6 years old. 5. Clinical efficacy of 6059-S in 6 cases pyelonephritis, 2 cases of sepsis, 1 case of meningitis, 1 case of intraperitoneal abscess, 9 cases pneumonia and 2 case of tonsillitis was 100%. In the case of urinary tract infection, 4 patients were treated successfully by the administration of 20 mg/kg/day of 6059-S. Other bacterial infections were treated with 55 to 200 mg/kg/day. 6. 100% of the causative organisms were eliminated by 6059-S. They were E. coli, Klebsiella pneumoniae, Serratia marcescens, H. influenzae and beta-Streptococcus. 7. No remarkable side effect was noticed during administration.
 ...
PMID:[Basic and clinical examinations of 6059-S in pediatrics (author's transl)]. 645 66

Pharmacokinetic and clinical studies of ampicillin suppository (KS-R1) was performed in children. The results were as follows. Peak serum level of ampicillin (ABPC) after single administration of KS-R1 contains 125 mg or 250 mg of ABPC in potency was 6.03 micrograms/ml after 15 minutes and 5.78 micrograms/ml after 30 minutes, respectively. The half-life was 30.4 minutes and 30.9 minutes, respectively. Urinary excretion rate was 34.2-70.1% within 6 hours. A clinical study of KS-R1 was performed in 40 patients including purulent tonsillitis (10 cases), pharyngitis (9 cases), bronchitis (6 cases), bronchopneumonia (2 cases), scarlet fever (8 cases), otitis media (1 case) and urinary tract infection (4 cases). The clinical effects, excellent and good responses, were showed in 37 cases (efficacy rate; 92.5%). No side effects and abnormal laboratory findings were observed.
 ...
PMID:[Experimental and clinical studies of an ampicillin suppository (KS-R1) in pediatrics]. 665 12

Clinical evaluations of ampicillin (ABPC) suppository (KS-R1) were performed in 9 cases with infectious diseases in the pediatric field and the following results were obtained; When 2.7 mg/kg of KS-R1 was rectally administered to 1 case, the plasma levels of ABPC were 3.9 micrograms/ml at 15 minutes, 2.2 micrograms/ml at 30 minutes and 1.2 micrograms/ml at 60 minutes after administration. The urinary excretion rate within 6 hours was 5.0%. Clinical effects of KS-R1 were examined in 6 cases (4 cases of tonsillitis and 2 cases of urinary tract infection) at the dose of 20 approximately 50 mg/kg/day for 3 approximately 7 days. Clinical responses were excellent in 4 cases, good in 1 case and poor in 1 case (tonsillitis). As to the side effects, slight increase of eosinophil was observed in 1 case, but no diarrhea, perianal redness and eruption were observed. Since discharge ratio of KS-R1 within 5 minutes was 11.0%, the tolerance of KS-R1 was considered to be good. From the above results, KS-R1 is useful for treating the pediatric patients with various infections, who refuse to oral administration or are impossible to give oral administration because of vomiting and are multiple handicapped ones.
 ...
PMID:[Clinical evaluation of an ampicillin suppository (KS-R1)]. 665 16

Cefpiramide (CPM) is a newly developed cephalosporin. Clinical studies on this drug were carried out and the results were as follows; Forty-three patients (purulent lymphadenitis 2, cellulitis 2, purulent otitis media 1, purulent tonsillitis 3, acute bronchitis 2, pneumonia 22, bronchiectasis 1, urinary tract infection 10) were treated with CPM, in doses of 20 approximately 82 mg/kg divided 2 approximately 4 times per day for 3 approximately 11 days intravenously. The overall efficacy rate was 83.7%. As to adverse reaction, 4 cases, which includes 3 cases of diarrhea and 1 case of exanthema, were observed. Abnormal laboratory data noted were liver dysfunction in 3 cases (6.8%), and eosinophilia in 2 cases (4.5%).
 ...
PMID:[Clinical evaluation of cefpiramide in pediatrics]. 665 35

T-1982 (cefbuperazone) is a newly developed cephamycin. Clinical studies on this drug were carried out and the results were as follows: Eighteen patients (pneumonia 13, purulent tonsillitis 1, acute bronchitis 1, cellulitis 1, urinary tract infection 2) were treated intravenously with daily 27.4-100.2 mg/kg of T-1982 in 3-4 divided dose for 3-6.7 days. The overall efficacy rate was 94.4%. No adverse reactions were observed. Abnormal laboratory data noted were liver dysfunction in 1 case (4.8%), eosinophilia in 2 cases (9.5%), and anemia in 1 case (4.8%).
 ...
PMID:[Clinical studies of T-1982 (cefbuperazone) in pediatric field]. 687 75

Five patients with suppurative tonsillitis (1), urinary tract infection (1), staphylococcal impetigo (1), cervical lymphadenitis (1) and mycoplasma pneumonia were treated with cefamandole (CMD). CMD was administered by one shot intravenous or drip infusion at a dosage of 100 approximately 135 mg/kg/day for 4 approximately 14 days. Of 5 patients with those infections, excellent response was obtained in 3 patients, good response in 1 patient and unknown response in 1 patient. The overall efficacy rate was 100% except unknown response in mycoplasma pneumonia. In 3 of these 5 cases causative organisms were S. epidermidis, E. coli, and S. aureus, respectively. These organisms were all eliminated. No side effects were observed.
 ...
PMID:[Laboratory and clinical studies of cefamandole in pediatric infections (author's transl)]. 699 32

The authors have carried out the laboratory and clinical studies of cefadroxil (CDX). The results were as follows; The sensitivity was measured by plate dilution method on 27 strains of S. aureus and E. coli, 26 strains of K. pneumoniae isolated from patients. The distribution of sensitivity of S. aureus was 3.13-12.5 microgram/ml and the peak of distribution was 3.13 microgram/ml and 6.25 microgram/ml, of E. coli was 6.25 microgram/ml by 10(8) cells/ml. And the distribution of sensitivity of K. pneumoniae was 6.25-25 microgram/ml and its peak was 6.25 microgram/ml by 10(8) cells/ml. CDX were given orally at dose of 10 mg/kg to 3 children. The serum levels of CDX were 10.5 +/- 1.78 microgram/ml, 15.8 +/- 3.25 microgram/ml, 12.0 +/- 0.41 microgram/ml and 3.9 +/- 0.9 microgram/ml at 0.5, 1, 2, 4 hours after administration respectively, and was 2.3 +/- 0.48 microgram/ml at 6 hours. The urinary excretion rate was 55.6% up to 8 hours after administration. CDX were administered to 39 cases of pediatric infectious disease (26 cases with tonsillitis, 5 cases with enterocolitis, 3 cases with UTI, 2 cases with impetigo, each one case with bronchitis, cervical lymphadenitis and epididymitis). And CDX were given 25.0-65.2 mg/kg daily. Clinical results obtained were above good in all cases. No side effects were observed in any cases, except for one case, with diarrhea, 6 cases with the elevation of serum transaminase and 1 case with eosinophilia.
 ...
PMID:[Laboratory and clinical studies of cefadroxil (author's transl)]. 701 97

Fundamental and clinical studies were made on cefadroxil, a new oral cephalosporin, and the following results were obtained. (1) Antibacterial activity of the drug against S. aureus, S. epidermidis, E. coli, Klebsiella, Salmonella and P. mirabilis was almost equal to that of cephalexin. The MIC of indole positive Proteus. Enterobacter, Citrobacter, S. marcescens and P. aeruginosa to cefadroxil was higher than 100 microgram/ml in almost all strains. (2) Serum concentrations following an oral administration of 10.0 to 14.3 mg/kg of cefadroxil dry syrup was highest at 2 hours in 2 cases and 1 hour in 1 case, respectively, which were 13.4 to 17.1 microgram/ml, and 1.8 to 6.8 microgram/ml at 4 hours with an T 1/2 of 1.04 to 1.62 hours and apparently longer continuation of serum concentration than that of cephalexin. Urinary recovery rate was 75-96% up to 6 hours. (3) Fourteen patients, i.e., 6 with tonsillitis and 8 with urinary tract infection, were treated with a daily oral dose of 30-50 mg/kg divided in 4 doses except 1 case divided in 3 doses. The overall efficacy rate was 100%, i.e., excellent in 13, good in 1 and no failure. Causative organisms disappeared in all cases. (4) Adverse reactions, such as diarrhea and skin rash, were not noted at all and 1 case presented a mild elevation of GOT and GPT. (5) Taste and flavor of the drug was well palatable to children. (6) Based on the above results, it is concluded cefadroxil dry syrup is a new potent cephalosporin for oral use in the treatment of acute bacterial infection in children. Daily dose of 40 mg/kg in 3-4 divided doses appeared to be appropriate.
 ...
PMID:[Fundamental and clinical studies on cefadroxil dry syrup in children (author's transl)]. 724 5

Laboratory and clinical investigations were performed on cefadroxil, and the results were obtained as follows. (1) Sensitivity distribution of cefadroxil. In S. aureus, two peaks were observed with inoculum size of 10(8)/ml: 1.56-3.13 microgram/ml and 12.5-25 microgram/ml, while with inoculum size of 10(8)/ml, the distribution was in the range of smaller than or equal to 0.1-25 microgram/ml, and the sensitivity peak was 0.78-1.56 microgram/ml. In S. pyogenes, with inoculum size of 10(8)/ml, sensitivity distribution was in the range of 0.05-1.56 microgram/ml, and the peak was 0.05 microgram/ml. On the other hand, with inoculum size of 10(6)/ml, distribution was 0.0006-1.56 microgram/ml, and the peak was 0.0006-0.012 microgram/ml, thus sensitivity of cefadroxil being 2 tubes higher. In E. coli, with inoculum size of 10(8)/ml, strains showed mostly high resistance as more than 100 microgram/ml, whereas with inoculum size of 10(6)/ml sensitivity was distributed between 3.13-50 microgram/ml, and the peak was 12.5-25 microgram/ml. (2) Absorption and excretion of cefadroxil: A dose of cefadroxil 5 mg/kg, 10 mg/kg or 20 mg/kg was administered to 9 cases of children aged from 4 years and 6 months to 11 years and 9 months, and serum levels of the drug were measured. As the results, in the group of 5 mg/kg dosing, the value was 0.94 microgram/ml at 30 minutes, 3.55 microgram/ml at 60 minutes, 7.65 microgram/ml at 2 hours, 2.55 microgram/ml at 4 hours, and 1.09 microgram/ml at 6 hours. In the group of 10 microgram/ml dosing, value of the drug was 4.18 microgram/ml at 30 minutes, 10.70 microgram/ml at 1 hour, 12.75 microgram/ml at 2 hours, 8.05 microgram/ml at 4 hours, and 2.33 microgram/ml at 6 hours. In the group of 20 mg/kg dosing, value was 9.93 microgram/ml at 30 minutes, 18.43 microgram/ml at 1 hour, 24.70 microgram/ml at 2 hours, 15.50 microgram/ml at 4 hours, and 6.45 microgram/ml at 6 hours. Dose response was observed thus distinctly among 3 groups. Recovery ratio of cefadroxil in urine was 76.14% within 6 hours. (3) Clinical trial with cefadroxil: Cefadroxil was applied clinically in 80 cases (76 patients). These included 22 cases of lacunar tonsillitis, 13 cases of pharyngitis, 24 cases of bronchitis, 6 cases of pneumonia, 8 cass of urinary tract infection, 5 cases of hemolytic streptococcal infection, 1 case of cellulitis, and 1 case of otitis media. Efficacy was obtained in 72 cases out of 80 cases ratio being thus 90%. Change of organisms was proven in 35 cases, among which disappearance and reduction of organism were observed in 32 cases (91.45). No adverse reaction was noticed throughout all cases. No abnormal value was recognized in laboratory findings.
 ...
PMID:[Laboratory and clinical studies on cefadroxil in the field of pediatrics (author's transl)]. 724 7


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>